Abdulaziz Mohammed Alamri

Dr. Abdulaziz Mohammed Alamri

King Saud University, Riyadh, Ar Riyāḑ, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
Syed Luqman AliSyed Luqman Ali
Syed Luqman Ali
Awais ALiAwais ALi
Awais ALi
Abdulaziz Mohammed AlamriAbdulaziz Mohammed Alamri
Abdulaziz Mohammed Alamri
ABAliya Baiduissenova
Aliya Baiduissenova
MDMarat Dusmagambetov
Marat Dusmagambetov
AAAigul Abduldayeva
Aigul Abduldayeva
Songling virus (SGLV), a newly discovered tick-borne orthonairovirus, was recently identified in human spleen tissue. It exhibits cytopathic effects in human hepatoma cells and is associated with clinical symptoms including headache, fever, depression, fatigue, and dizziness, but no treatments or vaccines exist for this pathogenic virus. In the current study, immunoinformatics techniques were employed to identify potential vaccine targets within SGLV by comprehensively analyzing SGLV proteins. Four proteins were chosen based on specific thresholds to identify B-cell and T-cell epitopes, validated through IFN-γ epitopes. Six overlap MHC-I, MHC-II, and B cell epitopes were chosen to design a comprehensive vaccine candidate, ensuring 100% global coverage. These structures were paired with different adjuvants for broader protection against international strains. Vaccine constructions’ 3D models were high-quality and validated by structural analysis. After molecular docking, SGLV-V4 was selected for further research due to its lowest binding energy (-66.26 kcal/mol) and its suitable immunological and physiochemical properties. The vaccine gene is expressed significantly in E. coli bacteria through in silico cloning. Immunological research and MD simulations supported its molecular stability and robust immune response within the host cell. These findings can potentially be used in designing safer and more effective experimental SGLV-V4 vaccines.

21 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MKMOHD KHAN
MOHD KHAN
MAMajed S. Alokail
Majed S. Alokail
AAAmal Alenad
Amal Alenad
NANojood Altawijry
Nojood Altawijry
NANouf AlAfaleq
Nouf AlAfaleq
MZMubarak Ali Zawba
Mubarak Ali Zawba
Alpha-amylase (α-amylase) is a key player in the management of diabetes and its related complications. This study was intended to have an insight into the binding of caffeic acid and coumaric acid with α-amylase and analyze the effect of these compounds on the formation of advanced glycation end-products (AGEs). Fluorescence quenching studies suggested that both the compounds showed an appreciable binding affinity towards α-amylase. The evaluation of thermodynamic parameters (ΔH and ΔS) suggested that the α-amylase-caffeic/coumaric acid complex formation is driven by van der Waals force and hydrogen bonding, and thus complexation process is seemingly specific. Moreover, glycation and oxidation studies were also performed to explore the multitarget to manage diabetes complications. Caffeic and coumaric acid both inhibited fructosamine content and AGE fluorescence, suggesting their role in the inhibition of early and advanced glycation end-products (AGEs). However, the glycation inhibitory potential of caffeic acid was more in comparison to p-coumaric acid. This high antiglycative potential can be attributed to its additional –OH group and high antioxidant activity. There was a significant recovery of 84.5% in free thiol groups in the presence of caffeic acid, while coumaric attenuated the slow recovery of 29.4% of thiol groups. In vitro studies were further entrenched by in silico studies. Molecular docking studies revealed that caffeic acid formed six hydrogen bonds (Trp 59, Gln 63, Arg 195, Arg 195, Asp 197 and Asp 197) while coumaric acid formed four H-bonds with Trp 59, Gln 63, Arg 195 and Asp 300. Our studies highlighted the role of hydrogen bonding, and the ligands such as caffeic or coumaric acid could be exploited to design antidiabetic drugs.

16 December 2024 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
Awais ALiAwais ALi
Awais ALi
Syed Luqman AliSyed Luqman Ali
Syed Luqman Ali
Abdulaziz Mohammed AlamriAbdulaziz Mohammed Alamri
Abdulaziz Mohammed Alamri
EKElham Mohammed Khatrawi
Elham Mohammed Khatrawi
ABAliya Baiduissenova
Aliya Baiduissenova
GAGulsum Askarova
Gulsum Askarova
Astrovirus MLB1 (HAstV-MLB1) is non-enveloped RNA virus that cause acute gastroenteritis infection. Despite research progress about infection and pathogenesis of HAstV-MLB1, Currently, no vaccine has been developed to effectively combat this pathogen. The current study is based on immunoinformatics and reverse vaccinology approaches to design next-generation, multi-epitope-based vaccine models against HAstV-MLB1. Genome-wide whole proteome data of HAstV-MLB1 strain was retrieved, and a series of analyses were conducted to explore effective B and T-cell epitopes that hold significant antigenic nature with no toxicity and allergenicity. A set of vaccine constructs were designed by different combination of lead B and T-cell epitopes with diverse linkers and adjuvants sequences. The model vaccine structures were analyzed via rigorous criteria of physiochemical properties, antigenicity, and molecular docking with HLA and TLR4 immune receptors to ensure their efficacy and safety. Based on the lowest binding energy of −82.48 kcal/mol against the HLA receptor, the MLB1-C2 vaccine model with β-definsin adjuvant was prioritized for molecular dynamic and immune simulations analyses to assess its stability and immunogenic potential. These analyses revealed that the MLB1-C2 construct has feasible molecular stability and potential to boost strong immune responses in the host cell. Besides, the model was predicted to be non-toxic, non-allergenic, and antigenic, ensuring broad population coverage and capable to elicit a robust immune response. The in-silico cloning analysis highlighted a possible gene expression potential of the MLB1-C2 construct in E.coli commercial recombinant vector molecule. The findings of the current study provide an essential template for the development of a advanced next-generation effective vaccine against HAstV-MLB1.

17 March 2025 in Medicina
Verified
Journal Article
Open access
PDF file
Amr ShehabeldineAmr Shehabeldine
Amr Shehabeldine
BBBahaa M. Badr
Bahaa M. Badr
FEFathy Mustafa Elkady
Fathy Mustafa Elkady
TWToru Watanabe
Toru Watanabe
MAMostafa A. Abdel-Maksoud
Mostafa A. Abdel-Maksoud
AAAmer Morsy Abdelaziz
Amer Morsy Abdelaziz
Background and Objectives: This study introduces an innovative approach to accelerating wound healing by leveraging the bactericidal properties of mycosynthesized copper oxide nanoparticles (CuO-NPs) and their combination with curcumin against Pseudomonas aeruginosa. The study aims to evaluate their antimicrobial efficacy, impact on quorum sensing-associated virulence factors, and potential therapeutic applications in wound healing. Materials and Methods: The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of CuO-NPs were determined to be 25 μg/mL and 50 μg/mL, respectively. At sub-inhibitory concentrations (0.5 MIC, 0.25 MIC, and 0.125 MIC), their effects on P. aeruginosa growth and quorum sensing-associated virulence factors were assessed. Antioxidant activity and cytotoxicity were also evaluated. Additionally, the combination of CuO-NPs and curcumin (CUR) was tested for its enhanced wound-healing efficacy. Results: While CuO-NPs did not inhibit P. aeruginosa growth at sub-inhibitory concentrations, they significantly reduced quorum sensing-associated virulence factors in a dose-dependent manner: LasB elastase (81.8%, 60.6%, and 53.03%), LasA protease (70%, 68.5%, and 57.1%), and pyocyanin (85.7%, 71.4%, and 55.9%). CuO-NPs exhibited strong antioxidant activity by scavenging free radicals. The combination of CuO-NPs and CUR demonstrated the highest wound-healing efficacy, outperforming the negative control and Mebo ointment by 193.9% and 61.6%, respectively. Additionally, CuO-NPs exhibited selective cytotoxicity against HepG2 cancer cells while displaying minimal toxicity toward normal human skin cells. Conclusions: CuO-NPs, particularly in combination with CUR, show promising potential as a therapeutic agent for wound healing by inhibiting quorum sensing-associated virulence factors, exhibiting strong antioxidant activity, and demonstrating selective cytotoxicity. These findings highlight their potential biomedical applications.

5 September 2024 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
Awais ALiAwais ALi
Awais ALi
Abdulaziz Mohammed AlamriAbdulaziz Mohammed Alamri
Abdulaziz Mohammed Alamri
HAHajar AZRAIDA
Hajar AZRAIDA

16 November 2024 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
Syed Luqman AliSyed Luqman Ali
Syed Luqman Ali
Awais ALiAwais ALi
Awais ALi
WUWaseef Ullah
Waseef Ullah
Abdulaziz Mohammed AlamriAbdulaziz Mohammed Alamri
Abdulaziz Mohammed Alamri
EKElham Mohammed Khatrawi
Elham Mohammed Khatrawi
PPPrasanta Kumar Parida
Prasanta Kumar Parida
The coronavirus that causes serious acute respiratory syndrome. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a major problem in public health and biomedicine. Even if there is no cure for it, the infection is still progressing naturally, and the only time that optimal treatment choices, such as doxycycline, work is at the beginning of the infection. Our project is structured into two critical parts: the first focuses on the identification of potential drug targets, and the second on vaccine design, both aimed at exploring new ways to treat the disease. Initially, cytoplasmic proteins identified through subtractive analysis underwent comprehensive evaluation for potential drug targeting, focusing on metabolic pathways, homology prediction, drugability assessment, essentiality, and protein–protein interactions. Subsequently, surface proteins underwent rigorous assessment for allergenicity, antigenicity, physiochemical attributes, conserved regions, protein interactions, and identification of B and T cell epitopes. Molecular docking and immunological simulation analyses were then employed to develop and characterize a multi-epitope vaccine, integrating findings from the aforementioned evaluations. Findings from the study point to six proteins as potential critical therapeutic targets for SARS-CoV-2, each of which is involved in a distinct metabolic process. The reverse vaccinology analysis suggested that the following proteins could be used as vaccine candidates: sp|P05106, sp|O00187, sp|Q9NYK1, sp|P05556, sp|P09958, and sp|Q9HC29. Four multi-epitope vaccine named as SARS-COV-2-, C1, C2, C3, and C4 was designed by utilizing different adjuvants and eighteen B cell overlapped epitopes which were predicted from top ranked protiens. Based on immune simulation study, the vaccine exhibited adequate immune-reactivity and favorable encounters with toll-type receptors (TLR4, TLR8, HLA, etc ACE), Among them the SARS-COV-2-C2 showed best binding affinity of which all receptors. Findings from this study could be a game-changer in the quest to develop a vaccine and medication that effectively combat SARS-CoV-2. It is necessary to do additional experimental analyses, nevertheless.